Real-world therapy and persistence of patients with neovascular age-related macular degeneration and diabetic retinopathy or diabetic macular edema: a German claims data analysis
Epidemiologic and ophthalmologic factors associated with anti-VEGF non-persistence were successfully identified in the first year of therapy. The analyzed dataset can potentially be enriched with additional health insurance database sets under the used criteria to gain more understanding of anti-VEGF non-persistence.
Authors
- Oliver Cox (ORCID: https://orcid.org/0000-0002-2308-7837)
- Julia Krieger
- Ulf Maywald
- S. Mueller (ORCID: https://orcid.org/0000-0003-4889-3058)
- Michael Koss (ORCID: https://orcid.org/0000-0002-5932-0418)
- Jan-Paul Flacke
- Lena Beilschmidt
Institutions
- Roche (Switzerland) (CH)
- Wismar University of Applied Sciences (DE)
- Roche Pharma AG (Germany) (DE)
- Blindeninstitutsstiftung (DE)
Publication Details
- Journal
- Graefe s Archive for Clinical and Experimental Ophthalmology
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1007/s00417-024-06690-9
- Citations
- 5
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.69
Funders
- Roche
- F. Hoffmann-La Roche